Pathogenetic treatment of mastopathy and prevention of breast cancer

Pathogenetic treatment of mastopathy and preventionof breast cancer V.G. Bespalov N.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of Health, Saint Petersburg, Russian Federation The review article discusses the relationship between an etiology and risk factors for benign breast disease (BBD) and breast cancer (BC), the pathogenesis of BBD due to an increased risk of BC, a risk assessment of BC in patients with BBD; pathogenetic treatment of BBD, aimed at preventing BC; an application of the drug Mamoclam® for the treatment of BBD and prevention of BC. BBD and BC have a common etiology and most risk factors are the same for both pathologies. Multiple risk factors disrupt the hormonal balance in a woman’s body, cause hyperestrogenism and epithelium hyperproliferation in the mammary tissue, which leads to the development of BBD, and in the presence of congenital or acquired gene damage, BBD increases the risk of BC. Crucial in assessing the risk degree of BC in patients with BBD is a morphological study of the mammary tissue obtained by biopsy. The risk of BC does not increase or is minimal with non-proliferative forms of BBD and increases significantly with proliferative BBD and precancerous lesions, such as atypical hyperplasia and carcinoma in situ. Mamoclam® is a non-hormonal drug containing organically bound iodine as an active substance. Mamoclam® is effective and safe drug for the pathogenetic treatment of BBD, with prolonged use reduces the risk of BC. Key words: benign breast disease, breast cancer, risk factors, etiology, pathogenesis, precancerous lesions, prevention, treatment of benign breast disease, Mamoclam. For citation: Bespalov V.G. Pathogenetic treatment of mastopathy and prevention of breast cancer. Russian Journal of Woman and Child Health. 2018;1(2):141–147.